Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
1 month ago
Video Series
Cardio-oncology Practice in an Eastern European Country
Added:
1 month ago
Expert Opinion
Added:
4 months ago
Dr Tom De Potter (Cardiovascular Center, OLV Hospital, Aalst, BE) joins us to share his expert perspective on the five key developments poised to transform atrial fibrillation and electrophysiology practice in 2026.This forward-looking discussion examines emerging technologies, evolving clinical evidence, and shifting treatment paradigms that will influence day-to-day decision-making in…
View more
Added:
4 months ago
Arrhythmia Academy Editor-in-Chief Dr Luigi Di Biase shares his expert perspective on the most practice-changing clinical trials emerging from the latest advances in atrial fibrillation management.In this highlights discussion, Dr Di Biase distills the key evidence that is reshaping clinical decision-making in AF ablation, anticoagulation strategies, and rhythm control approaches. Drawing from…
View more
Added:
2 months ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes…
View more
Added:
2 months ago
ACC 2026 — Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, US) delivers his expert verdict on three late-breaking clinical trials from ACC 2026 that are poised to influence cardiovascular care and future clinical guidelines.Dr Bhatt highlights data updates from the SURPASS-CVOT trial, exploring expanded cardiometabolic findings with tirzepatide versus dulaglutide, discusses the HI-PEITHO…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 - Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) joins us to discuss the evolving understanding of the causal relationship between elevated lipoprotein(a) and atherosclerotic cardiovascular disease, and what this means for risk stratification and management strategies in clinical practice.Dr O'Donoghue begins by highlighting the importance for clinicians to…
View more
Added:
1 year ago
ACC 2025 - In this succinct video, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute & University of California, CA, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:FRESH-UPAPI-CATALIGN-ARPROTECT-TAVIRecorded on-site at ACC in Chicago, 2025.Support: This is an independent interview…
View more
Added:
1 year ago
ACC 2025 - In this highlights video, Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:STRIDESOULFRESH-UPFAIR-HF 2Recorded on-site at ACC in Chicago, 2025.Support: This is an independent interview produced by Radcliffe…
View more
Added:
7 months ago
TCT 2025 - In this comprehensive highlights video from TCT 2025, Prof Rasha Al-Lamee (Imperial College Healthcare NHS Trust, UK) delivers an expert analysis of the groundbreaking late-breaking trials that are set to reshape interventional cardiology practice.Join Prof Al-Lamee as she breaks down the pivotal studies driving innovation in cardiovascular care and discusses their implications for…
View more